Sugi Predict

Sugi Predict / Compounds / SCHEMBL1607763

SCHEMBL1607763

SCHEMBL1607763

CC(C)(C)OC(=O)N[C@H]1CC[C@H](C=O)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 1/20 0.50
▸ KDM1A O60341 1/20 0.47
▸ MAOB P27338 1/20 0.47
▸ CTSK P43235 2/20 0.47
▸ GAA P10253 2/20 0.45
▸ EPHX1 P07099 1/20 0.44
▸ CA1 P00915 1/20 0.43
▸ CA2 P00918 1/20 0.43
▸ DRD2 P14416 3/20 0.41
▸ NFKB1 P19838 1/20 0.41
▸ NFKB2 Q00653 1/20 0.41
▸ RELA Q04206 1/20 0.41
▸ EPHX2 P34913 1/20 0.40
▸ JAK1 P23458 2/20 0.40
▸ JAK2 O60674 1/20 0.40
▸ TYK2 P29597 1/20 0.40
▸ JAK3 P52333 1/20 0.40
▸ CYP2C9 P11712 1/20 0.39
▸ HSD11B1 P28845 1/20 0.39
▸ KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1422443 1.00 BTK (0.50) BTKKDM1AMAOBCTSKGAA
SCHEMBL2963241 1.00 BTK (0.50) BTKKDM1AMAOBCTSKGAA
SCHEMBL23819397 0.90 BTK (0.55) BTKKDM1AMAOBCTSKGAA
SCHEMBL3901035 0.90 BTK (0.55) BTKKDM1AMAOBCTSKGAA
SCHEMBL14941189 0.90 BTK (0.55) BTKKDM1AMAOBCTSKGAA
SCHEMBL15584728 0.90 BTK (0.55) BTKKDM1AMAOBCTSKGAA
SCHEMBL13639056 0.90 BTK (0.55) BTKKDM1AMAOBCTSKGAA
SCHEMBL10343938 0.87 BTK (0.61) BTKKDM1AMAOBCTSKGAA
SCHEMBL3702152 0.87 BTK (0.61) BTKKDM1AMAOBCTSKGAA
SCHEMBL3702157 0.87 BTK (0.61) BTKKDM1AMAOBCTSKGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119751529-B Nucleotide dimer, preparation method and application thereof Beijing Xuanjingrui Pharmaceutical Technology Co.,Ltd. (CN) 2026-05-26 — — CN disclosed
EP-4745239-A1 CFB INHIBITOR COMPOSITION AND USE THEREOF Rigerna Therapeutics Co., Ltd. (CN) 2026-05-20 — — EP disclosed
CN-122070362-A Nucleic acid chimeras comprising multiple double-stranded oligonucleotide molecules, compositions, and uses thereof 北京炫景瑞医药科技有限公司 2026-05-19 — — CN disclosed
EP-4709720-A1 INHIBITORS AND DEGRADERS OF PIP4K PROTEIN Larkspur Biosciences, Inc. (US) 2026-03-18 — — EP disclosed
EP-4707392-A1 DOUBLE-STRANDED OLIGONUCLEOTIDE, CONJUGATE THEREOF, AND USE THEREOF Rigerna Therapeutics (Beijing) Co., Ltd. (CN) 2026-03-11 — — EP disclosed
US-20260009029-A1 COMPOUND FOR INHIBITING EXPRESSION OF LPA GENE, PHARMACEUTICAL COMPOSITION AND USE THEREOF RIGERNA THERAPEUTICS SUZHOU CO LTD (CN) 2026-01-08 — — US disclosed
US-20260009030-A1 COMPOUND FOR INHIBITING AGT GENE EXPRESSION, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF RIGERNA THERAPEUTICS SUZHOU CO LTD (CN) 2026-01-08 — — US disclosed
EP-4171567-B1 CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH CELGENE CORP (US) 2025-09-03 — — EP disclosed
EP-4171568-B1 CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH CELGENE CORP (US) 2025-08-27 — — EP disclosed
EP-4600358-A1 COMPOUND FOR INHIBITING C3 GENE EXPRESSION, PHARMACEUTICAL COMPOSITION AND USE THEREOF Rigerna Therapeutics (Suzhou) Co., Ltd. (CN) 2025-08-13 — — EP disclosed
EP-1884510-A1 N-SUBSTITUTED PHENYLACETAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME Dainippon Sumitomo Pharma Co., Ltd. (JP) 2008-02-06 — — EP disclosed
US-20060148800-A1 Pyrimidines as PLK inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-07-06 — — US disclosed
US-20060079484-A1 Phosphinyloxy, oxime and carboxylic acid derivatives which are useful as carboxypeptidase U inhibitors LINSCHOTEN MARCEL 2006-04-13 — — US disclosed
US-20050176766-A1 2,3-Oxidosqualene-lanosterol cyclase inhibitors ACKERMANN JEAN (CH) 2005-08-11 — — US disclosed
US-6858651-B2 2,3-oxidosqualene-lanosterol cyclase inhibitors HOFFMANN-LA ROCHE INC. (US) 2005-02-22 — — US disclosed
EP-1311475-A1 NOVEL AMINOCYCLOHEXANE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-05-21 — — EP disclosed
US-20020045777-A1 2,3-oxidosqualene-lanosterol cyclase inhibitors F.HOFFMANN-LA ROCHE AG (CH) 2002-04-18 — — US disclosed
WO-2002014267-A1 NOVEL AMINOCYCLOHEXANE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2002-02-21 — — WO disclosed
EP-1180099-A1 NEW COMPOUNDS AstraZeneca AB (SE) 2002-02-20 — — EP disclosed
WO-2000066550-A1 NEW COMPOUNDS ASTRAZENECA AB (SE) 2000-11-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260009030-A1 COMPOUND FOR INHIBITING AGT GENE EXPRESSION, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF AGTR1, AGT, AGTR2 BTK 4860/4885KDM1A 4547/4885MAOB 1247/4885
US-20260009029-A1 COMPOUND FOR INHIBITING EXPRESSION OF LPA GENE, PHARMACEUTICAL COMPOSITION AND USE THEREOF LPAR6, LPAR2, LPAR1 BTK 4529/4885KDM1A 3310/4885MAOB 1695/4885
US-20050176766-A1 2,3-Oxidosqualene-lanosterol cyclase inhibitors CYP51A1, LSS, CYP46A1 BTK 3119/4885KDM1A 3842/4885MAOB 2190/4885
US-20060079484-A1 Phosphinyloxy, oxime and carboxylic acid derivatives which are useful as carboxypeptidase U inhibitors CPN1, CPA1, DNPEP BTK 2373/4885KDM1A 980/4885MAOB 125/4885
US-20060148800-A1 Pyrimidines as PLK inhibitors PLK2, PLK3, TYMP BTK 603/4885KDM1A 1073/4885MAOB 1887/4885
US-20020045777-A1 2,3-oxidosqualene-lanosterol cyclase inhibitors CYP51A1, LSS, CYP46A1 BTK 3119/4885KDM1A 3842/4885MAOB 2190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.